痛风患者支持性自我管理评估(GoutSMART):一项随机对照可行性试验
在苏格兰爱丁堡一家医院开展的随机对照可行性试验中,60例痛风患者按2:1分配至支持性自我管理组或常规护理组,24周时支持性自我管理组73%达到尿酸目标≤0.30 mmol/L,常规护理组为15%(风险差0.58,95%CI 0.37-0.78;p<0.0001),两组脱落率和不良事件无差异。
要点
- 支持性自我管理组24周尿酸达标率73%,常规护理组15%,风险差0.58(95%CI 0.37-0.78)。
- 90%的参与者完成研究,两组脱落率和不良事件无差异。
- 作者认为支持性自我管理耐受良好,需更大规模试验评估临床和成本效果。
核心结论
- 支持性痛风自我管理相比常规护理大幅提高尿酸目标达标率,且耐受良好;需更大规模试验以全面评估该方法的临床和成本效果。
研究设计与样本
- 随机对照可行性研究,在英国爱丁堡一家医院开展,纳入年龄≥18岁、有医生建议启动或升级降尿酸治疗的痛风患者。
- 参与者按2:1比例随机分配至支持性自我管理组或常规护理组,使用GoutSMART智能手机应用程序。
- 共筛查92例患者,2019年4月5日至2020年3月19日期间入组60例(65%);平均年龄52.8岁(SD 14.6),男性56例(93%),女性4例(7%),白人58例(97%)。
- 支持性自我管理组40例,常规护理组20例;主要结局为24周时达到尿酸目标≤0.30 mmol/L的参与者百分比,按意向治疗分析。
- 试验注册号ClinicalTrials.gov NCT03274063,另有扩展研究正在进行;参与者和评估者均未设盲。
主要发现
- 24周时支持性自我管理组29例(73%)达到尿酸目标≤0.30 mmol/L,常规护理组3例(15%)(风险差0.58,95%CI 0.37-0.78;p<0.0001)。
- 90%的参与者完成研究,两组脱落率和不良事件无差异。
关键数值与推荐
- 主要结局达标定义为24周时尿酸≤0.30 mmol/L。
- 支持性自我管理组达标29/40例(73%)vs 常规护理组3/20例(15%),风险差0.58(95%CI 0.37-0.78),p<0.0001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Improved outcomes for patients with gout are associated with the control of urate levels; yet, less than 40% of patients in the UK are currently offered urate lowering therapy, and it is typically offered without titration to target. Supported self-management has been shown to benefit patients with chronic health conditions; therefore, we aimed to determine whether a supported gout self-management approach, incorporating treatment-to-target urate, helped participants reach target urate levels. METHODS: In this randomised controlled feasibility study, conducted in one hospital in Edinburgh, UK, we included patients (aged ≥18 years) with gout and a physician recommendation for initiation or escalation of urate lowering therapy. We randomised participants in a 2:1 ratio to a supported self-management group or a usual care group using the GoutSMART smartphone app. Participants in the self-management group were given a urate self-testing meter and received direct advice from clinicians on escalation of urate lowering therapy through the app. Participants were identified following referral to rheumatology, or using the Scottish Health Research Register, and they were screened and offered a detailed management plan before randomisation. Participants in the usual care group had a limited version of the app, which only allowed it to function as a health diary, and their gout management plan was implemented by their general practitioner. The primary outcome was the percentage of participants achieving a urate target of 0·30 mmol/L or less at 24 weeks, and analysis was by intent to treat. The trial was registered with ClinicalTrials.gov, NCT03274063, and there is an extension study ongoing. There was no masking of participants or assessors. FINDINGS: Between April 5, 2019, and March 19, 2020, 60 (65%) of 92 patients screened were enrolled to the study. The mean age was 52.8 years (SD 14.6); 56 (93%) of the participants were male, and 4 (7%) were female. 58 (97%) of participants were White. 40 participants were assigned to the self-supported management group and 20 participants were assigned to the usual care group. A urate target of 0·30 mmol/L or less at 24 weeks was reached by 29 (73%) participants in the supported self-management group compared with 3 (15%) participants in the usual care group (risk difference 0·58 [95% CI 0·37-0·78]; p<0·0001). 90% of participants completed the study with no difference in the drop-out rate or adverse events between the two groups. INTERPRETATION: Supported self-management of gout results in substantially improved attainment of urate targets compared with usual care, and it is well tolerated. Larger trials will be needed to fully evaluate the clinical and cost-effectiveness of this approach. FUNDING: Edinburgh & Lothians Health Foundation.
引用
- Riches PL, Alexander D, Hauser B, et al. Evaluation of supported self-management in gout (GoutSMART): a randomised controlled feasibility trial. Lancet Rheumatol. 2022. PMID: 38294032. doi:10.1016/S2665-9913(22)00062-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。